Last updated: 2026-09-16 09:04:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Kiniksa Pharmaceuticals International, plc (KNSA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $75.20, with a market capitalisation of $5.98B and a P/E ratio of 72.70. Over the past 52 weeks, its price has ranged from $35.20 to $82.94. This page covers its latest market performance, valuation, price trends and company information.
$5.98B | |
$75.24 | |
$82.94 | |
$5.01 | |
$75.15 | |
63.00 | |
740.03K | |
72.70 | |
$82.94 | |
$35.20 | |
0.41% | |
-- |
Kiniksa Pharmaceuticals International, plc (KNSA) is trading at $75.20 in pre-market trading as of 2026-09-16 08:30:00, up 0.07% ($0.05) from the previous close of $75.15
Pre-market trading shows how investors are pricing KNSA before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Kiniksa Pharmaceuticals International, plc (KNSA) moved from $77.91 to $75.20, representing a decline of 3.48% ($2.71).
The stock traded between $74.47 and $80.43 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 552.45 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 83.8%
KNSA is currently trading at $75.20, placing it 83.8% of the way from its 52-week low of $35.20 to its 52-week high of $82.94. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 366 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kiniksa Pharmaceuticals International, plc (KNSA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.